60 related articles for article (PubMed ID: 28285371)
21. Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review.
Haugvik SP; Labori KJ; Edwin B; Mathisen Ø; Gladhaug IP
ScientificWorldJournal; 2012; 2012():357475. PubMed ID: 23304085
[TBL] [Abstract][Full Text] [Related]
22. Neutrophil-to-lymphocyte ratio predicts metachronous liver metastasis of pancreatic neuroendocrine tumors.
Arima K; Okabe H; Hashimoto D; Chikamoto A; Nitta H; Higashi T; Kaida T; Yamamura K; Kitano Y; Komohara Y; Yamashita YI; Beppu T; Takeya M; Baba H
Int J Clin Oncol; 2017 Aug; 22(4):734-739. PubMed ID: 28285371
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of the preoperative main pancreatic duct dilation and neutrophil-to-lymphocyte ratio in pancreatic neuroendocrine tumors (PNETs) of the head after curative resection.
Zhou B; Zhan C; Xiang J; Ding Y; Yan S
BMC Endocr Disord; 2019 Nov; 19(1):123. PubMed ID: 31718651
[TBL] [Abstract][Full Text] [Related]
25. Association of preoperative monocyte-to-lymphocyte and neutrophil-to-lymphocyte ratio with recurrence-free and overall survival after resection of pancreatic neuroendocrine tumors (US-NETSG).
Panni RZ; Lopez-Aguiar AG; Liu J; Poultsides GA; Rocha FG; Hawkins WG; Strasberg SM; Trikalinos NA; Maithel S; Fields RC;
J Surg Oncol; 2019 Sep; 120(4):632-638. PubMed ID: 31339198
[TBL] [Abstract][Full Text] [Related]
26. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages.
Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
Pancreatology; 2019 Sep; 19(6):897-902. PubMed ID: 31409525
[TBL] [Abstract][Full Text] [Related]
28. The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases.
Arima K; Okabe H; Hashimoto D; Chikamoto A; Tsuji A; Yamamura K; Kitano Y; Inoue R; Kaida T; Higashi T; Taki K; Imai K; Komohara Y; Beppu T; Takeya M; Baba H
Int J Clin Oncol; 2016 Oct; 21(5):940-945. PubMed ID: 27023215
[TBL] [Abstract][Full Text] [Related]
29. The Neutrophil-to-Lymphocyte Ratio Predicts Malignant Potential in Intraductal Papillary Mucinous Neoplasms.
Arima K; Okabe H; Hashimoto D; Chikamoto A; Kuroki H; Taki K; Kaida T; Higashi T; Nitta H; Komohara Y; Beppu T; Takeya M; Baba H
J Gastrointest Surg; 2015 Dec; 19(12):2171-7. PubMed ID: 26443528
[TBL] [Abstract][Full Text] [Related]
30. The up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan.
Ito T; Lee L; Hijioka M; Kawabe K; Kato M; Nakamura K; Ueda K; Ohtsuka T; Igarashi H
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):574-7. PubMed ID: 25689058
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of neutrophil lymphocyte ratio in patients with gastric cancer: a meta-analysis.
Zhang X; Zhang W; Feng LJ
PLoS One; 2014; 9(11):e111906. PubMed ID: 25401500
[TBL] [Abstract][Full Text] [Related]
32. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours.
Paramanathan A; Saxena A; Morris DL
Surg Oncol; 2014 Mar; 23(1):31-9. PubMed ID: 24378193
[TBL] [Abstract][Full Text] [Related]
33. Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after gastroenterostomy in patients with advanced pancreatic adenocarcinoma.
Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Okamura Y
Ann Surg Oncol; 2013 Dec; 20(13):4330-7. PubMed ID: 23982254
[TBL] [Abstract][Full Text] [Related]
34. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis.
Mano Y; Shirabe K; Yamashita Y; Harimoto N; Tsujita E; Takeishi K; Aishima S; Ikegami T; Yoshizumi T; Yamanaka T; Maehara Y
Ann Surg; 2013 Aug; 258(2):301-5. PubMed ID: 23774313
[TBL] [Abstract][Full Text] [Related]
35. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment.
Motomura T; Shirabe K; Mano Y; Muto J; Toshima T; Umemoto Y; Fukuhara T; Uchiyama H; Ikegami T; Yoshizumi T; Soejima Y; Maehara Y
J Hepatol; 2013 Jan; 58(1):58-64. PubMed ID: 22925812
[TBL] [Abstract][Full Text] [Related]
36. Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment.
Poultsides GA; Huang LC; Cameron JL; Tuli R; Lan L; Hruban RH; Pawlik TM; Herman JM; Edil BH; Ahuja N; Choti MA; Wolfgang CL; Schulick RD
Ann Surg Oncol; 2012 Jun; 19(6):1928-35. PubMed ID: 22167476
[TBL] [Abstract][Full Text] [Related]
37. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study.
Proctor MJ; Morrison DS; Talwar D; Balmer SM; Fletcher CD; O'Reilly DS; Foulis AK; Horgan PG; McMillan DC
Eur J Cancer; 2011 Nov; 47(17):2633-41. PubMed ID: 21724383
[TBL] [Abstract][Full Text] [Related]
38. Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review.
Capurso G; Bettini R; Rinzivillo M; Boninsegna L; Delle Fave G; Falconi M
Neuroendocrinology; 2011; 93(4):223-9. PubMed ID: 21358176
[TBL] [Abstract][Full Text] [Related]
39. Everolimus for advanced pancreatic neuroendocrine tumors.
Yao JC; Shah MH; Ito T; Bohas CL; Wolin EM; Van Cutsem E; Hobday TJ; Okusaka T; Capdevila J; de Vries EG; Tomassetti P; Pavel ME; Hoosen S; Haas T; Lincy J; Lebwohl D; Öberg K;
N Engl J Med; 2011 Feb; 364(6):514-23. PubMed ID: 21306238
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
